None of the trials of COVId-19 candidate vaccines can detect a reduction in serious outcomes such as hospitalization or death, a leading public health expert said Thursday.
Writing in the BMJ medical journal, associate editor Peter Doshi warned that not even phase 3 trials under way in the race for a vaccine can prove their product will prevent people contracting COVID-19.
In a sobering essay, Doshi said those hoping for a breakthrough to end the pandemic would be disappointed, with some vaccines likely to reduce the risk of infection by only 30 percent.
“None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths,” he wrote.
“Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.”